Get the Stockscreener App
2.80
2.10%
-0.06
After Hours:
2.65
-0.15
-5.36%
Alpha Tau Medical Ltd stock is traded at $2.80, with a volume of 119.83K.
It is down -2.10% in the last 24 hours and up +27.27% over the past month.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. The Alpha CaRT technology of the company utilizes the therapeutic properties of alpha particles aiming to overcome, and harness for benefit for alpha radiation's range. The company derives maximum revenue from Israel.
See More
Previous Close:
$2.86
Open:
$2.94
24h Volume:
119.83K
Relative Volume:
4.27
Market Cap:
$202.95M
Revenue:
-
Net Income/Loss:
$-27.63M
P/E Ratio:
-8.75
EPS:
-0.32
Net Cash Flow:
$-39.43M
1W Performance:
+22.00%
1M Performance:
+27.27%
6M Performance:
+10.67%
1Y Performance:
-8.50%
1-Day Range:
$2.7144
$2.98
1-Week Range:
$2.20
$2.98
52-Week Range:
$1.75
$3.40
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
Compare DRTS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRTS
Alpha Tau Medical Ltd
|
2.80 | 202.95M | 0 | -27.63M | -39.43M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-23 | Initiated | Citigroup | Buy |
| Apr-24-23 | Initiated | H.C. Wainwright | Buy |
| Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-22 | Initiated | Piper Sandler | Overweight |
| Apr-04-22 | Initiated | Citigroup | Buy |
Alpha Tau Medical Ltd Stock (DRTS) Latest News
Nyxoah (NASDAQ:NYXH) vs. Alpha Tau Medical (NASDAQ:DRTS) Head to Head Contrast - Defense World
Alpha Tau Medical Reports Q3 2024 Financial Results - TipRanks
HC Wainwright Reaffirms "Buy" Rating for Alpha Tau Medical (NASDAQ:DRTS) - MarketBeat
Piper Sandler reaffirms OW rating on Alpha Tau Medical shares as 'multiple milestones' line up - Investing.com South Africa
Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Alpha Tau Medical Advances in Cancer Treatment Technology - TipRanks
Alpha Tau Medical Advances Cancer Treatment Pipeline, Reports $68.4M Cash Position | DRTS Stock News - StockTitan
Alpha Emitter Market Size Expected to Hit USD 1751.5 Million by 2032, Expanding at a 11.25% CAGR: VMR - EIN News
DRTSWAlpha Tau Medical Ltd. Warrant Latest Stock News & Market Updates - StockTitan
Alpha Tau Medical Ltd. (NASDAQ:DRTS) Sees Significant Growth in Short Interest - MarketBeat
Short Interest in Alpha Tau Medical Ltd. (NASDAQ:DRTS) Grows By 30.5% - Defense World
Alpha Tau Medical to Showcase at Key Healthcare Conferences - TipRanks
Alpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36th Annual Healthcare Conference - The Manila Times
Alpha Tau to Participate in Citi’s 2024 Global Healthcare Conference and Piper Sandler’s 36th Annual Healthcare Conference - Marketscreener.com
Alpha Tau to Participate in Citi’s 2024 Global Healthcare - GlobeNewswire
Alpha Tau CFO to Present Alpha DaRT Cancer Therapy at Major Healthcare Conferences | DRTS Stock News - StockTitan
Alpha Tau Medical to Hold Annual Shareholder Meeting - TipRanks
Alpha Tau Medical : Notice and proxy statement for the annual general meeting of shareholders of the Company to be held on December 17, 2024 Form 6 K - Marketscreener.com
Medical Lasers Market Growth and Technology 2024 - openPR
MasterCraft Boat Holdings, Inc. (NASDAQ:MCFT) Receives $19.20 Average Target Price from Analysts - Defense World
Spire Global, Inc. (NYSE:SPIR) Receives $13.67 Average Target Price from Brokerages - Defense World
Brinker International (NYSE:EAT) Sets New 52-Week High After Analyst Upgrade - Defense World
Invesco Solar ETF Target of Unusually High Options Trading (NYSEARCA:TAN) - Defense World
Traders Buy High Volume of Call Options on Nutrien (NYSE:NTR) - Defense World
Brokerages Set Silvaco Group, Inc. (NASDAQ:SVCO) PT at $20.83 - Defense World
Analysts Set Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) PT at $34.60 - Defense World
Orthofix Medical (NASDAQ:OFIX) and Alpha Tau Medical (NASDAQ:DRTS) Financial Contrast - Defense World
Top 230+ startups in Radiation Therapy Devices in Nov, 2024 - Tracxn
Comparing Alpha Tau Medical (NASDAQ:DRTS) and Beyond Air (NASDAQ:XAIR) - Defense World
Discover Alpha Tau Medical And 2 Other US Penny Stocks - Simply Wall St
Head-To-Head Review: Biotricity (NASDAQ:BTCY) vs. Alpha Tau Medical (NASDAQ:DRTS) - Defense World
HC Wainwright Reiterates "Buy" Rating for Alpha Tau Medical (NASDAQ:DRTS) - MarketBeat
Alpha Tau Joins FDA Program to Advance Cancer Therapy - TipRanks
Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme - The Manila Times
Alpha Tau Announces Acceptance Into FDA’s Total Product - GlobeNewswire
Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme - Yahoo Finance
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
Alpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Update - MarketBeat
Alpha Tau Medical (NASDAQ:DRTS) Stock Rating Reaffirmed by HC Wainwright - Defense World
Alpha Tau Medical shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com Canada
Alpha Tau’s Alpha DaRT Advances Lung Cancer Treatment - Yahoo Finance
Alpha Tau Medical shares maintain Buy rating from H.C. Wainwright - Investing.com
Alpha Emitter Market Size to witness nearly $1751.5 Million By 2032 - 대구포스트
Alpha Tau treats first lung cancer patient with radiation therapy in Jerusalem - Mugglehead
Alpha Tau Treats First Patient with Recurrent Lung Cancer - ForexTV.com
Alpha Tau Medical Ltd. Treats First Patient with Recurrent Lung Cancer - Marketscreener.com
Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer - Marketscreener.com
Radiopharmaceutical Market 2024 – Industry Opportunities, Challenges, Value Chain and Sales Channels Analysis 2032 | Clarity Pharmaceuticals - 대구포스트
Short Interest in Alpha Tau Medical Ltd. (NASDAQ:DRTS) Expands By 23.9% - MarketBeat
Alpha Emitter Market Outlook, Key Trends and Growth Projections from 2024 to 2032 - 대구포스트
Alpha Emitter Market on the Rise: A Study on its Growth Prospects - openPR
Alpha Tau Medical Ltd Stock (DRTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):